{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:17:40Z","timestamp":1768738660140,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,12,30]],"date-time":"2018-12-30T00:00:00Z","timestamp":1546128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Gr\u00fcnenthal, Aachen, Germany"},{"name":"Danish Agency for Science, Technology"},{"name":"Innovation and the Danish National Research Foundation"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.biopha.2018.12.130","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T20:58:19Z","timestamp":1546981099000},"page":"926-933","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis \u2013 Effects of a peroxisome proliferator-activated receptor gamma (PPAR-\u03b3) agonist and a glucagon-like peptide-1 analogue"],"prefix":"10.1016","volume":"111","author":[{"given":"Samuel J.","family":"Daniels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana J.","family":"Leeming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9466-2333","authenticated-orcid":false,"given":"S\u00f6nke","family":"Detlefsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria F.","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara T.","family":"Hjuler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Hein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten A.","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Brockbank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Cruwys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2018.12.130_bib0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0010","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030","volume":"0","author":"Estes","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0015","series-title":"EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-Alcoholic Fatty Liver Disease","author":"Association for the Study of the Liver, E","year":"2015"},{"key":"10.1016\/j.biopha.2018.12.130_bib0020","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/hep.28860","article-title":"Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood","volume":"65","author":"Decaris","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2018.12.130_bib0025","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2018.12.130_bib0030","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.biopha.2018.12.130_bib0035","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2018.12.130_bib0040","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","article-title":"Triggering and resolution of inflammation in NASH","volume":"15","author":"Schuster","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0045","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2018.12.130_bib0050","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jhep.2017.10.031","article-title":"Preclinical models of non-alcoholic fatty liver disease","volume":"68","author":"Santhekadur","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0055","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2018.12.130_bib0060","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2018.12.130_bib0065","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstr\u00f6m","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.phrs.2015.03.005","article-title":"Effect of resveratrol on experimental non-alcoholic steatohepatitis","volume":"95\u201396","author":"Heeb\u00f8ll","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2018.12.130_bib0075","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/hep.22363","article-title":"Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of nonalcoholic steatohepatitis","volume":"48","author":"Wouters","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2018.12.130_bib0080","first-page":"E37","article-title":"Cholate inhibits high-fat diet-induced hyperglycemia and obesity with acyl-CoA synthetase mRNA decrease","volume":"273","author":"Ikemoto","year":"1997","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0085","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2018.12.130_bib0090","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2018.12.130_bib0095","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(18)30474-4","article-title":"NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"391","author":"Harrison","year":"2018","journal-title":"Lancet (Lond. Engl.)"},{"issue":"5","key":"10.1016\/j.biopha.2018.12.130_bib0100","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2018.12.130_bib0105","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0168-8278(17)30443-9","article-title":"BMS-986036 (pegylated FGF21) in patients with non-alcoholic steatohepatitis: a phase 2 study","volume":"66","author":"Sanyal","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0110","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2018.12.130_bib0115","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0120","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2018.12.130_bib0125","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003495-200666010-00005","article-title":"Pioglitazone: a review of its use in type 2 diabetes mellitus","volume":"66","author":"Waugh","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2018.12.130_bib0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mce.2008.11.018","article-title":"Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue","volume":"297","author":"Russell-Jones","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0135","doi-asserted-by":"crossref","first-page":"8364","DOI":"10.3748\/wjg.v20.i26.8364","article-title":"Experimental models of non-alcoholic fatty liver disease in rats","volume":"20","author":"Kucera","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0140","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2018.12.130_bib0145","doi-asserted-by":"crossref","first-page":"e115922","DOI":"10.1371\/journal.pone.0115922","article-title":"Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology","volume":"9","author":"Liang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2018.12.130_bib0150","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1053\/j.semdp.2006.11.003","article-title":"Granulomas in the liver","volume":"23","author":"Kleiner","year":"2006","journal-title":"Semin. Diagn. Pathol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0155","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.3748\/wjg.v16.i40.5065","article-title":"Hepatic lipogranulomas in patients with chronic liver disease: association with hepatitis C and fatty liver disease","volume":"16","author":"Zhu","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0160","first-page":"G295","article-title":"Experimental nonalcoholic steatohepatitis compromises ureagenesis, an essential hepatic metabolic function","volume":"307","author":"Thomsen","year":"2014","journal-title":"Am. J. Physiol. Liver Physiol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0165","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/oby.21563","article-title":"The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity","volume":"24","author":"Hjuler","year":"2016","journal-title":"Obesity"},{"key":"10.1016\/j.biopha.2018.12.130_bib0170","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1002\/hep.21763","article-title":"A lipidomic analysis of nonalcoholic fatty liver disease","volume":"46","author":"Puri","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.biopha.2018.12.130_bib0175","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2018.12.130_bib0180","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3748\/wjg.v24.i2.179","article-title":"Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis","volume":"24","author":"T\u00f8lb\u00f8l","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0185","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.amjcard.2009.03.023","article-title":"Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14)","volume":"104","author":"Spanheimer","year":"2009","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.biopha.2018.12.130_bib0190","article-title":"Pioglitazone improves hepatic mitochondrial function in a mouse model of nonalcoholic steatohepatitis","author":"Kalavalapalli","year":"2018","journal-title":"Am. J. Physiol. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2018.12.130_bib0195","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/labinvest.3700489","article-title":"Intrahepatic insulin resistance in a murine model of steatohepatitis: effect of PPAR\u03b3 agonist pioglitazone","volume":"87","author":"Leclercq","year":"2007","journal-title":"Lab. Invest."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218366137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218366137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T11:40:48Z","timestamp":1760096448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218366137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":39,"alternative-id":["S0753332218366137"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.12.130","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis \u2013 Effects of a peroxisome proliferator-activated receptor gamma (PPAR-\u03b3) agonist and a glucagon-like peptide-1 analogue","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.12.130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}